+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.

Age: 18Years - 75YearsAll GendersPhase 3
77 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
E

Actively Recruiting

Researchers are evaluating BG-C477, a targeted antibody-drug conjugate, in adults with advanced solid tumors that cannot be removed by surgery or have spread to other parts of the body. This Phase 1ab study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity of BG-C477 alone and in combination with other anticancer agents. BG-C477 targets a protein called CEA on lung cancer cells to deliver a drug that prevents cancer cell multiplication and causes cell death. The study includes two parts Phase 1a tests increasing doses of BG-C477 alone to find a safe dose without serious side effects. Phase 1b evaluates the selected dose further, either alone or combined with chemotherapy or tislelizumab. BG-C477 is administered intravenously. Participants receive treatment during these phases, with sequential dose escalation and expansion cohorts. The treatment duration is about 9 months for Phase 1a and approximately 18 months for Phase 1b. Participants will attend regular clinic visits for treatment administration, health assessments, blood tests, tumor evaluations, and imaging studies. Researchers will monitor adverse events, determine the recommended dose levels, and assess tumor response and progression using standardized criteria. Safety and pharmacokinetic data will be collected up to about two years after the last dose. Overall participation lasts up to 18 months depending on the study phase.

Age: 18Years +All GendersPhase 1
59 locations
P

Actively Recruiting

Researchers are evaluating the combination of calderasib and pembrolizumab as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation and a PD-L1 tumor proportion score of 50% or higher. The study aims to determine if this combination improves progression-free survival compared to pembrolizumab with placebo. This is a phase 3 randomized, double-blind trial sponsored by Merck Sharp & Dohme LLC. Participants will receive pembrolizumab 200 mg through intravenous infusion on the first day of each 21-day cycle, continuing for up to 35 cycles. In addition, they will take either calderasib or placebo tablets daily until they meet discontinuation criteria. The study includes two groups one receiving calderasib plus pembrolizumab and the other receiving placebo plus pembrolizumab. No new participants will be offered a second course of pembrolizumab. Throughout the study, participants will undergo various assessments including tumor evaluations by central review to measure progression-free survival, overall survival, and response rates. Quality of life and physical functioning will be monitored using standardized questionnaires up to 24 months. Safety will be tracked by recording adverse events and treatment discontinuations for up to approximately 80 months. The total study duration extends up to 7 years, with ongoing monitoring throughout.

Age: 18Years +All GendersPhase 3
246 locations
E

Actively Recruiting

Researchers are studying the safety, tolerability, and effectiveness of DS-3939a, alone or combined with other cancer treatments, in people with solid tumors, including locally advanced unresectable or metastatic non-squamous non-small cell lung cancer NSCLC. The study is an open-label trial with two independent substudies focusing on different patient groups and treatment combinations, including immunotherapy and chemotherapy. It aims to better understand how these treatments work in advanced lung cancer cases. Participants receive intravenous infusions of DS-3939a every three weeks, either alone or combined with pembrolizumab, carboplatin, pemetrexed, or DS-1103a, depending on their subgroup. The study has two parts for each substudy dose escalation Part 1 to find the recommended dose, followed by dose expansion Part 2 where participants are randomized to different treatment groups. Treatments continue until disease progression or other reasons for stopping treatment. During the study, participants will have regular assessments including imaging scans to monitor tumor response based on RECIST v1.1 criteria, safety evaluations, and blood tests to measure drug levels. Researchers will track side effects, tumor shrinkage, disease control, and survival over several years. The study also includes long-term monitoring of drug concentrations and immune responses. Participants can expect frequent visits for treatments and evaluations throughout the study period.

Age: 18Years +All GendersPhase 1Phase 2
76 locations
O

Actively Recruiting

Researchers are evaluating the real-world effectiveness and safety of Trastuzumab Deruxtecan T-DXd in patients with unresectable or metastatic HER2-positive or HER2-low breast cancer. This observational study focuses on patients who have previously received anti-HER2 treatments or systemic therapy and aims to understand treatment outcomes, patient characteristics, and tolerability over time. The study is sponsored by Daiichi Sankyo and collects detailed clinical and patient-reported data to provide insights into treatment patterns and safety. Participants are grouped into two cohorts those with HER2-positive breast cancer who have had one or more anti-HER2 regimens, and those with HER2-low breast cancer who have received prior systemic therapy or experienced early recurrence after adjuvant chemotherapy. All participants are starting or have recently started T-DXd treatment according to approved labeling in China. The study observes these patients from the start of treatment until study end, death, withdrawal, loss to follow-up, or closure. During the study, researchers will track time to next treatment or death, treatment duration, dosing changes, safety events, and patient-reported tolerability using questionnaires and symptom diaries. Follow-up lasts up to 36 months with ongoing data collection on clinical characteristics, treatment patterns, and safety management. This design allows for a comprehensive view of how T-DXd performs in routine clinical practice for this patient population.

Age: 18Years +All Genders
54 locations
E

Actively Recruiting

Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.

Age: 18Years - 80YearsAll GendersPhase 3
61 locations
A

Actively Recruiting

Researchers are investigating the effects of art therapy on motor function recovery in patients who have experienced a subacute ischemic stroke. This study focuses on the critical subacute recovery phase, which occurs days to weeks after the stroke, when rehabilitation efforts can significantly influence long-term outcomes. The study aims to compare the impact of art therapy with regular therapy in improving motor function during this period. Participants will be randomly assigned to receive either art therapy or regular therapy. Art therapy includes activities such as music, painting, and dance, which help regulate emotions, reduce anxiety and depression, and stimulate different brain areas to encourage neuroplasticity and motor recovery. The study intervention period covers the subacute stroke phase, specifically between two weeks and three months after stroke onset. During the study, participants will undergo assessments including the Fugl-Meyer Assessment at one month to measure motor function improvement. Researchers will monitor participants physical and cognitive abilities, emotional status, and communication skills to ensure effective participation. The study is designed to provide insights into how art therapy may support rehabilitation in stroke survivors aged 40 to 75, with mild to moderate stroke effects.

Age: 40Years - 75YearsAll GendersPhase Not Applicable
1 location
A

Actively Recruiting

Stroke is a leading cause of disability and death worldwide, with increasing cases due to an aging population. Many stroke patients experience long-term challenges beyond physical impairments, such as emotional, cognitive, and social difficulties. This trial evaluates art therapy as a supportive treatment during the subacute phase of stroke recovery, aiming to improve these non-motor functions through creative activities. The study compares two groups one receiving art therapy involving music, painting, dance, and other creative forms designed to regulate emotions, reduce anxiety and depression, and promote brain plasticity and the other receiving regular standard therapy. Art therapy serves as an additional rehabilitation approach alongside traditional treatments during the critical recovery period between 2 weeks and 3 months after stroke. Participants will attend therapy sessions and undergo assessments focused on emotional and cognitive recovery. Researchers will measure depression levels after one month to evaluate the therapys impact. The study includes monitoring participants physical and mental abilities, ensuring they can engage in therapy activities and complete the intervention. The entire participation period aligns with the subacute recovery phase, targeting mild to moderate stroke sequelae.

Age: 40Years - 75YearsAll GendersPhase Not Applicable
1 location

1-10 of 25

1